- Ticker
- ALEC
- Price
- 6.37
- Stock movement up
- +0.54 (9.26%)
- Company name
- Alector Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 613.97M
- Ent value
- 998.00M
- Price/Sales
- 6.37
- Price/Book
- 3.43
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 15.30%
- 1 year return
- -1.09%
- 3 year return
- -41.18%
- 5 year return
- -19.42%
- 10 year return
- -
Last updated: 2024-07-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ALEC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.37 |
| Price to Book | 3.43 |
| EV to Sales | 10.35 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 96.38M |
| EPS (TTM) | -1.29 |
| FCF per share (TTM) | -2.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 96.41M |
| Gross profit (TTM) | 83.04M |
| Operating income (TTM) | -145.33M |
| Net income (TTM) | -120.61M |
| EPS (TTM) | -1.29 |
| EPS (1y forward) | -1.66 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 86.13% |
| Operating margin (TTM) | -150.75% |
| Profit margin (TTM) | -125.11% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 72.55M |
| Net receivables | 0.00 |
| Total current assets | 581.39M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 45.16M |
| Total assets | 635.49M |
| Accounts payable | 4.59M |
| Short/Current long term debt | 37.56M |
| Total current liabilities | 164.92M |
| Total liabilities | 456.59M |
| Shareholder's equity | 178.91M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -196.96M |
| Capital expenditures (TTM) | 2.08M |
| Free cash flow (TTM) | -199.04M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -67.42% |
| Return on Assets | -18.98% |
| Return on Invested Capital | -64.35% |
| Cash Return on Invested Capital | -106.19% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.77 |
| Daily high | 6.43 |
| Daily low | 5.74 |
| Daily Volume | 1.09M |
| All-time high | 39.49 |
| 1y analyst estimate | 13.75 |
| Beta | 0.77 |
| EPS (TTM) | -1.29 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 1 Aug 2024 |
Downside potential
Loading...
Downside potential data
| ALEC | S&P500 | |
| Current price drop from All-time high | -83.87% | -1.81% |
| Highest price drop | -90.45% | -56.47% |
| Date of highest drop | 13 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -56.39% | -11.26% |
| Avg time to new high | 62 days | 12 days |
| Max time to new high | 765 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
613.97M
Marketcap category
Small-cap
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Employees
244
Website
Investor relations
-
SEC filings
CEO
Arnon Rosenthal
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page